Lymphotoxin alpha1 beta2 and LIGHT (LTα1β2 and LIGHT)

Lymphotoxin alpha1 beta2 (LTα1β2) is a membrane-bound heterotrimeric cytokine consisting of one lymphotoxin alpha (LTα) and two lymphotoxin beta (LTβ) subunits, primarily expressed by activated T and B lymphocytes and natural killer cells. It is a key ligand for the lymphotoxin-beta receptor (LTβR), orchestrating the development and maintenance of lymphoid tissues, regulation of immune responses, and inflammatory signaling. Disruption of LTα1β2-LTβR signaling impairs B cell activation, T cell differentiation, and the formation of immune microenvironments such as Peyer's patches[1][3][5][7]. LIGHT (TNFSF14) is another member of the TNF superfamily functioning as both a membrane-bound and soluble cytokine. It can bind LTβR, HVEM, and the decoy receptor DcR3, mediating activation and migration of lymphocytes, dendritic cells, and myeloid cells, and modulating inflammation, cell survival, and apoptosis. LIGHT–HVEM and LIGHT–LTβR interactions contribute to lymph node formation, immune regulation, antitumor activity, and metabolic functions[7][9]. Both LTα1β2 and LIGHT are studied as immunological targets for the treatment of chronic inflammation, autoimmune disorders, and cancer, but their broad immunobiological roles raise concerns about systemic immunosuppression and tissue-specific complications[3][7][9].

Other names

Lymphotoxin-alpha1-beta2 (LT-alpha1-beta2)Lymphotoxin beta (when referring to LTα1β2 complex)LIGHT (TNFSF14)Tumor necrosis factor ligand superfamily member 14 (for LIGHT)LTα1/β2LTα/β heterotrimer (for LTα1β2)TNFSF3 (for Lymphotoxin complex)TNFSF14 (for LIGHT)LTA and LTB (gene symbols: LTA for LTα, LTB for LTβ)

Inhibition of LTβR signaling (by blocking ligands or receptor) impairs lymphoid organogenesis and inflammatory signaling, attenuating immune activity[3][5]. Antagonism of LIGHT suppresses HVEM and LTβR activation, inhibiting T cell and dendritic cell activation, and can reduce tissue inflammation[7][9]. Blocking LTα1β2-LTβR or LIGHT-LTβR/HVEM interaction can downregulate NF-κB signaling pathways and reduce the expression of chemokines and adhesion molecules[3][5].